ST. PETERSBURG, Fla.,
July 12, 2019 /PRNewswire-PRWeb/ --
Ted Danson on CNBC will be hosting
an interview of the MMJ International Holdings executives focusing
on scientific research for the advancement of medical
marijuana-based pharmaceuticals in an upcoming episode, scheduled
to broadcast July 14, 2019 @
1:30p.m. on CNBC. Check your local
listings for more information.
With two investigational new drug applications already accepted
by the FDA, MMJ International Holdings (MMJIH) is working to bring
relief to patients suffering from Multiple Sclerosis and
Huntington's disease. This segment of advancements TV will focus on
the science of medical cannabis and how our development of a
pharmaceutical medicine of THC and cannabidiol, or CBD, is going to
help people manage symptoms associated with Multiple Sclerosis,
Huntington's and other like neurological diseases.
"MMJ is excited to be part of this breakthrough episode of
Advancements TV," said CEO of MMJ International Holdings,
Duane Boise. He continued, "We would
like to commend the series on its vision and foresight in
recognizing the need to educate audiences about the science of
medical cannabis. MMJIH has always been an advocate for creating
awareness about the value of marijuana-based pharmaceuticals. We
believe that this industry is about to undergo a massive
transformation and we are honored to be leader in the evolution of
it."
"MMJIH truly cares about helping people," said Tim Moynahan, MMJIH Chairman "Using innovative
technology, MMJ is helping to drastically cut drug development
costs to obtain approval for an insurance reimbursable medicine.
Patients are in need of a safe and effective marijuana-based
pharmaceuticals to manage their unmet medical needs."
About MMJIH:
MMJ International Holdings is dedicated to advancing the science of
medical Cannabis. Having been awarded the FDA Orphan Designation,
MMJIH is intent on bringing relief to patients around the world
with its innovative and well FDA researched medical products. MMJ's
journey continues to prove the efficacy of cannabis as an FDA
approved medicine while its unique scientific approach further
distinguishes MMJ from others in the industry.
For more information, visit: http://www.mmjih.com.
SOURCE MMJ International Holdings